Israeli pharmaceutical giant Teva said Monday that it was buying the generic drug business of Allergan for $40.5 billion, consolidating its position as a world leader in generics.

Teva will pay $33.75 billion in cash and offer $6.75 billion of its stock to Allergan, the company said, in a major move that will further shake up the industry.